To date, treatment with NIM-1324 has reduced the production of interferon alpha in blood from systemic lupus erythematosus (SLE) patients and provided protection from clinical disease and tissue ...

is a peptide-based therapy designed for systemic lupus erythematosus (SLE). Its mechanism of action revolves around modulating autophagy, a process involved in immune system regulation.

HCQ and chloroquine have a recognised role as DMARDs in the treatment of RA, Sjogren’s disease and systemic lupus erythematosus ... storage disorder due to the inhibition of constitutive autophagy ...

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes ...

Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

Long-term use of glucocorticoids (GCs) for the treatment of lupus is very common, however, it has also been associated with side effects like high blood pressure, diabetes, infection, and osteoporosis ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

Systemic lupus erythematosus (SLE) can have links with sleep disorders such as insomnia and obstructive sleep apnea. Lupus can also make you wake up more in the night. If lupus is affecting the ...

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of ...